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Comment on ‘Anti-tumour activity of
abiraterone and diethylstilboestrol when
administered sequentially to men with
castration-resistant prostate cancer’
J Shamash*,1 and S-J Sarker2
1St Bartholomew’s Hospital, 7th Floor, Gloucester House, Little Britain, UK and 2Centre for Experimental Cancer Medicine, Queen
Mary University of London, London, UK
Omlin et al (2013) report the anti-tumour activity of diethylstilbestrol
(DS) and abiraterone (AA) in castration-resistant prostate cancer and
suggest substantial activity of AA in DS pretreated patients. Their
retrospective review includes patients who were post docetaxel as well
as those who were chemotherapy naive. We feel that the additional
activity of AA may have been overstated. Abiraterone is always
combined with a corticosteroid – and therefore the comparison is
between AA and a corticosteroid vs DS and a corticosteroid. Most of
the patients in the series described by Omlin et al (2013) received DS
without a corticosteroid. In the paper by Ryan et al (2013) median
time to progression (TTP) was doubled when AA and prednisone
was compared with prednisone alone (11.1 vs 5.6 months). When the
combination of dexamethasone and DS was compared to dex-
amethasone alone, a similar effect was seen (8.6 vs 4.5 months) in
chemotherapy-naive patients (Shamash et al, 2011), see table below.
Dexamethasone with deferred DS vs dex-
amethasone and DS (Shamash et al,
2011)
Prednisone vs AA and
prednisone (Ryan et al,
2013)
Randomisation Yes Yes
Double blind No Yes
ECOG PS 0–3 0–1
PSA progression PCWG1 PCWG2
Patients All chemo naı¨ve All chemo naive
PFS (rad) Not stated 16.5 vs 8.3
Median TTP (PSA) All: 8.5, dexamethasone alone: 4.5, DdS*
(overall): 8.4, DS: 8.6
Prednisone: 5.6 AA/pre-
dnisone: 11.1
Median overall survival (OS) All: 19.1 (95% CI: 16.8–21.4), DdS: 18.8,
DS: 19.4
(33% went on to receive chemotherapy)
27.2 vs 427.2
Median OS (PS¼ 0) All: 28.7, DdS: 26.2,
DS: 38.1
427.2
HR for survival 0.79 (0.57–1.08): DS vs DdS 0.75 (0.61–0.93)
HR for survival (PS¼ 0) 0.63 (0.33, 1.2) 0.71 (0.55, 0.92)
PSA decline X50% All: 66%, dexamethasone alone: 50%, DS
68%
Prednisone 24% vs AA/
prednisone 62%
DdS* DS was added when the patient progressed.
We feel that some of the responses described could also
be explained by the fact that DS was given before docetaxel and
AA after. There is evidence that chemotherapy following failure of
a hormone therapy allows that treatment to work again when
patients are rechallenged with the same hormone therapy.
We have reviewed our data on patients who went on to receive
DS and dexamethasone followed on progression by AA and
prednisolone. We have identified 12 patients who had DS and
dexamethasone immediately prior to AA and prednisolone. Eleven
had prior treatment with docetaxel. Five out of 12 had a 50% PSA
response to DS. Progression-free survival was 7.0 months (range
3.6–8.7), for the whole group it was 3.4 months (range 1.1–8.7).
For subsequent AA and prednisolone only one patient responded
(PFS 8.1 months). The overall PFS was 1.8 months (range 0.6–8.1).
For the 11 who received docetaxel, 10 had prior DS. Five out
of 10 had a 50% PSA response with a PFS of 7.0 months
(range 1.0–15.0). For this group, overall PFS was 5.75 months
(range 1–15). Four out of these five subsequently re-responded
following docetaxel.
This supports our view that many patients who respond to
hormone therapy prechemotherapy will subsequently respond to
the same hormonal therapy afterwards (Shamash et al, 2008) and
that cross-resistance between AA and DS when combined with
steroids may be much greater than has been suggested.
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Sir,
We thank Shamash and Sarker for their interest in our recent
article (Omlin et al, 2013). They make three comments: first, that
the activity of diethylstilboestrol (DES) when combined with a
corticosteroid such as dexamethasone (D) is increased compared to
DES alone; second, that chemotherapy may re-induce sensitivity to
a hormonal agent; finally, their experience in 11 patients who
received the sequence of docetaxel followed by DES and D and
then abiraterone acetate (AA) and prednisone. In this setting the
activity of AA was limited, as indicated by a median progression-
free survival (PFS) of 1.8 months (range 0.6–8.1).
We wish to clarify that we did not report any data on
DES activity prior to treatment with AA because it was not possible
to get complete DES activity data for patients treated outside of our
institution. We therefore only reported duration of DES treatment.
Our large institutional experience with single-agent DES and
aspirin in 231 men with castration resistant prostate cancer
(CRPC) showed a median time to PSA progression of 4.6 months,
X50% PSA declines in 28.9% of patients and a VTE rate of 9.9%
(Wilkins et al, 2012). We acknowledge that the activity of DES
may be modestly higher when it is combined with D, which
has been shown to have single-agent anti-tumour activity in men
with castration-resistant prostate cancer, although there is little
evidence that this therapeutic manoeuvre imparts significant
clinical benefit (Venkitaraman et al, 2008). The comparison of
DES plus D with D alone by Shamash et al (2011) is interesting but
raised concerns that DES is associated with a major risk of serious
toxicity, unlike AA, with veno-thromboembolic events (VTEs) in
22% of patients despite prophylactic treatment with aspirin. Given
that AA provides overall survival benefit in Phase III trials, AA is a
preferable treatment to DES for CRPC (de Bono et al, 2011;
Ryan et al, 2013). Indeed we believe that there may now
be little merit in administering DES to patients suffering
from CRPC.
The hypothesis that chemotherapy may induce sensitivity to
endocrine agents is also intriguing. However, clinical trials of AA
and enzalutamide have all reported higher response rates pre-
chemotherapy than afterwards, suggesting overlapping mechan-
isms of resistance (Scher et al, 2010, 2012; de Bono et al, 2011;
Ryan et al, 2013). The study referenced by Shamash et al (2008) did
not utilise taxanes (that through their postulated disruption of AR
signalling may be associated with cross-resistance with endocrine
treatments) and allowed cessation of androgen deprivation with
49% of patients having non-castrate levels of testosterone at the
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